dc.contributor.author | Montelius, Mikael | |
dc.date.accessioned | 2016-11-18T12:48:18Z | |
dc.date.available | 2016-11-18T12:48:18Z | |
dc.date.issued | 2016-11-18 | |
dc.identifier.isbn | 978-91-628-9963-9 (print) | |
dc.identifier.isbn | 978-91-628-9964-6 (PDF) | |
dc.identifier.uri | http://hdl.handle.net/2077/44927 | |
dc.description.abstract | Clinical assessment of tumour response to treatment largely relies on estimates of tumour size
by, e.g., measuring the largest tumour diameters on magnetic resonance (MR) or computed
tomography (CT) images, weeks or months after treatment. However, most tumours are
heterogeneous, and treatment may result in different effects in different parts of the tumour.
Therefore, non-invasive methods sensitive to biological effects that precede changes in tumour
size would improve our understanding of tumour biology and therapeutic effects, facilitate
personalized treatments and speed up development of anti-cancer therapeutics. MR methods
have the potential to provide non-invasive imaging biomarkers of the relevant tumour biology,
but the understanding of the information provided by MR methods is still limited.
The aim of this project to was to improve the understanding and evaluate the feasibility of
multiparametric MR methods for therapy response assessment of tumours after radionuclide
therapy.
Mice xenografted with human neuroendocrine tumours received 15 MBq 177Lu-octreotate i.v.
on day 0, and MR imaging experiments were performed on days -1, 1, 3, 8 and 13, using
dynamic contrast enhanced-, quantitative T1 and T2*- and diffusion weighted MR on a 7T
small animal MR system. Optimization studies were performed to improve tissue model
parameter estimates, and to ensure accurate MR based tumour volume estimation for response
verification. MR parameter maps were spatially registered to corresponding histologically
stained tumour section for correlation analysis, and tumour tissue samples were analysed using
quantitative proteomics.
Several statistically significant correlations were found between MR parameters and histological
tumour characteristics, as well as with proteins associated with radiobiological effects on
tumours, and collectively evaluated they provided information on apoptotic and proliferative
activity, microvascular density and fibrosis in tumours, which are all important prognostic
tumour characteristics. Spatial and temporal MR parameter variations before and after therapy
seem to be predictive of tumour shrinkage or stabilization. Most effects on MR parameters were
seen already one day after treatment initiation.
This work demonstrates the feasibility of multiparametric MR for therapy response assessment
in an animal tumour model, and highlights the importance of spatial and temporal evaluation of
the MR parameters. Future efforts should include improvement of methods for spatial
registration of in vivo MR images and ex vivo histological sections. For clinical applications,
MR acquisition times need to be reduced. | sv |
dc.language.iso | eng | sv |
dc.relation.haspart | I. Montelius M et al. Tumour size
measurement in a mouse model using high resolution MRI. BMC Medical Imaging. 2012;12:12. ::doi::10.1186/1471-2342-12-12 | sv |
dc.relation.haspart | II. Gustafsson O et al. Impact of Prior
Distributions and Central Tendency Measures in Bayesian Intravoxel Incoherent
Motion Model Fitting. Manuscript | sv |
dc.relation.haspart | III. Montelius M et al. Multiparametric MR evaluation of small intestine neuroendocrine tumour tissue characteristics correlated to histological analyses. Manuscript | sv |
dc.relation.haspart | IV. Montelius M et al. Identification of potential MR derived biomarkers for tumour tissue response to 177Lu-octreotate therapy in an animal model of small intestine neuroendocrine tumour. Manuscript | sv |
dc.subject | Cancer | sv |
dc.subject | Functional imaging | sv |
dc.subject | IVIM | sv |
dc.subject | MRI | sv |
dc.subject | DWI | sv |
dc.subject | DCE | sv |
dc.subject | histology | sv |
dc.subject | 177Lu-octreotate | sv |
dc.subject | small intestine neuroendocrine tumour | sv |
dc.subject | NET | sv |
dc.subject | diffusion | sv |
dc.subject | perfusion | sv |
dc.subject | semi-quantitative | sv |
dc.subject | proteomics | sv |
dc.subject | ionizing radiation | sv |
dc.subject | biology | sv |
dc.subject | imaging biomarker | sv |
dc.title | Multiparametric MRI for evaluation of tumour treatment response | sv |
dc.title.alternative | Studies of 177Lu-octreotate therapy of neuroendocrine tumour | sv |
dc.type | text | eng |
dc.type.svep | Doctoral thesis | eng |
dc.gup.mail | mikael.montelius@vgregion.se | sv |
dc.gup.mail | mikael.montelius@radfys.gu.se | sv |
dc.type.degree | Doctor of Philosophy (Medicine) | sv |
dc.gup.origin | University of Gothenburg. Sahlgrenska Academy | sv |
dc.gup.department | Institute of Clincial Sciences. Department of Radiation Physics | sv |
dc.gup.defenceplace | Fredagen den 9 december 2016, kl. 13.00, sal Europa, Konferenscentrum Wallenberg, Medicinaregatan 20A, Göteborg | sv |
dc.gup.defencedate | 2016-12-09 | |
dc.gup.dissdb-fakultet | SA | |